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Abstract CardioARM, a highly Xexible “snakelike” med-
ical robotic system (Medrobotics, Raynham, MA), has been
developed to allow physicians to view, access, and perform
complex procedures intrapericardially on the beating heart
through a single-access port. Transthoracic epicardial cath-
eter mapping and ablation has emerged as a strategy to treat
arrhythmias, particularly ventricular arrhythmias, originating
from the epicardial surface. The aim of our investigation was
to determine whether the CardioARM could be used to
diagnose and treat ventricular tachycardia (VT) of epicar-
dial origin. Animal and clinical studies of the CardioARM
Xexible robot were performed in hybrid surgical–electro-
physiology settings. In a porcine model study, single-port
pericardial access, navigation, mapping, and ablation were
performed in nine animals. The device was then used in a
small, single-center feasibility clinical study. Three
patients, all with drug-refractory VT and multiple failed
endocardial ablation attempts, underwent epicardial map-
ping with the Xexible robot. In all nine animals, navigation,
mapping, and ablation were successful without hemody-
namic compromise. In the human study, all three patients
demonstrated a favorable safety proWle, with no major
adverse events through a 30-day follow-up. Two cases
achieved technical success, in which an electroanatomic
map of the epicardial ventricle surface was created; in the
third case, blood obscured visualization. These results,
although based on a limited number of experimental ani-
mals and patients, show promise and suggest that further
clinical investigation on the use of the Xexible robot in
patients requiring epicardial mapping of VT is warranted.
Keywords Ventricular tachycardia · Electroanatomical 
epicardial mapping · Catheter ablation · Robotic assisted 
procedure · Flexible robot · Minimally invasive surgery
Introduction
A “snakelike” robot system has been developed to enable
physicians to perform complex procedures intrapericar-
dially on a beating heart without having to open the chest
cavity. The CardioARM, developed by Medrobotics (Rayn-
ham, MA, USA), allows surgeons to take a curvilinear
approach to a surgical target rather than the straight line-of-
sight directed approach used in traditional laparoscopic and
thoracoscopic surgeries. The multilinked Xexible robot
contains multiple open device channels to accept a variety
of Xexible surgical and interventional tools, as well as
on-board visualization. The robot needs only a single point
of entry and one hand to steer it to the target site under
direct visualization. It contains multiple degrees of freedom
distributed across its links and is self-supporting, enabling the
robot to traverse nonlinear paths in any three-dimensional
space without relying on a lumen or organ to maintain its
shape [1–6].
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determine whether the CardioARM can be used success-
fully in the diagnosis and treatment of ventricular tachycardia
(VT). For this type of arrhythmia, percutaneous, transve-
nous, endocardial radiofrequency (RF) ablation has become
a secondary treatment strategy when antiarrhythmic drugs
and implantable cardioverter-deWbrillators (ICDs) fail [7–10].
Yet when critical components of the arrhythmia involve
epicardial or subepicardial structures, ablation via the endo-
cardial approach is challenging [10–14]. Prior to the catheter-
based endocardial ablation methods, surgical techniques for
ablating arrhythmia substrates from an epicardial approach
were more common. However, the invasiveness of these
techniques, which include open-chest surgery [15, 16], tho-
racoscopy [17, 18], and entering via epicardial vessels such
as the coronary sinus [19], has warranted research into
other methods.
Subxiphoid percutaneous epicardial catheter mapping
and ablation was Wrst described in 1996, and in the inter-
vening interval this clinical strategy has gained acceptance
and is being used at an increasing frequency to diagnose
and treat VT when critical components of the arrhythmia
may involve structures in the epicardium or subepicardium
irregardless if the VT is dependent on the re-entry circuit or
focal origin [10–14, 20, 21]. This approach, however, has
its own challenges, including gaining access safely and
eYciently to the pericardial space without complication,
manipulating and controlling catheters originally designed
for use within blood vessels, avoiding sensitive structures
in which damage can have serious, long-term consequences
[22], and delivering enough ablative energy in an environ-
ment where electrode contact, presence of epicardial fat,
and myocardial scars may present obstacles.
Single-site subxiphoid approaches by both electrophysi-
ologists and cardiac surgeons have previously been
described [11, 23–28]. Sosa and Scanavacca [11] described
a subxiphoid approach for epicardial mapping; however,
their technique (1) requires signiWcant standard Xuoroscop-
ically guided catheter manipulation and (2) lacks suYcient
visualization of epicardial landmarks. A hybrid surgical
approach using the FlexView system avoids both of these
issues, but this system can only provide limited access to
small regions of the heart [26]. Because of its rigidity, this
video-guided approach may be associated with signiWcant
hemodynamic compromise and potential arrhythmia, at
least in the porcine model [27].
In this report, we present results from both animal and
clinical studies of a Xexible robot system which we per-
formed in hybrid electrophysiology (EP) surgical settings.
The aim of these trials was to demonstrate that the Xexible
robot can access the pericardial space through a small sin-
gle-site entry and safely navigate all left and right ventricle
surfaces on a beating heart while at the same time enabling
direct visualization and mapping of the epicardium with




The CardioARM medical robotic system (Medrobotics,
Raynham, MA) is a highly articulated robot platform
designed to enable intrapericardial beating heart interven-
tions through a single entry point. Once inserted into the
pericardial free space, the Xexible robot is designed to
access all outer surfaces of the beating heart conWned
within the pericardium.
The core technology is the working end of the robot
(Fig. 1), which is manipulated through an external control
motor and sensor box placed near the patient and is com-
puter-controlled by a physician interface either at the bedside
or in a remote application. Previous animal investigational
work with an earlier prototype of this device has been
described [1–6]. The robot’s Xexibility and motion come
from having over 30 mechanical linkages in two concentric
mechanisms. Each mechanism can be placed into a rigid or
a Xexible state. By employing a “follow-the-leader” move-
ment strategy [1, 28] with these two alternating states (rigid
and Xexible), the self-supporting robot can be directed into
any shape bounded by the sum of the individual articulating
joints and does not require a natural lumen or organ surface
to maintain its shape. The robot contains multiple open
device channels that can be Wtted with a Wberoptic visuali-
zation system, a catheter for suction or delivery of addi-
tional tools, and a catheter for mapping and ablation
(Fig. 1). In these studies a CARTO Thermocool Navistar
catheter (Biosense Webster, Diamond Bar, CA) was used to
produce bipolar voltage maps of ventricles and deliver
radiofrequency energy during ablation therapy. An 8-Fr Softip
Guide catheter (Boston ScientiWc, Natik, MA) was delivered
through the remaining channel for suction.
Animal lab experience
Initial studies of the CardioARM to gain experience with the
navigation and ablation tasks were performed on nine female
pigs (weight range 40.2–50.0 kg; mean weight 45.2 kg). In
the initial study (4 animals), investigators looked at hemody-
namic impact and the deliverability of tools without the aid
of a mapping system. In the subsequent study (5 animals),
full integration of the equipment later to be used in the clini-
cal trial was examined. After each pig had been given general
anesthesia, pericardial access was gained through a 3- to 4-cm
midline skin incision below the xiphoid process (n = 7) or123
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procedure was attempted to mimic the approach to the
human heart (see Discussion section for additional details).
The physician removed the xiphoid process and created
a 15-mm opening on the pericardium, which was retracted
with stay sutures or via Allis clamps. The Xexible robot was
introduced into the intrapericardial space and guided between
the pericardial and epicardial spaces. It was manipulated
from the computer-controlled joystick to access various
intrapericardial structures, including the ventricular surface
and other structures contained within the pericardium. No
other incisions were created to allow operation of the robot.
Navigation was achieved under Wberoptic camera guidance,
which allowed for intrapericardial visualization of anatomi-
cal objects and catheters, and was periodically checked by
Xuoroscopy.
Commercially available RF ablation catheters, which
were passed through the robot’s working channels, were
used to map and create epicardial lesions. Vital physio-
logical parameters were continuously monitored during
the intrapericardial manipulations and ablations. Fluoros-
copy was used to verify the real-time position recorded by
the CARTO system (Biosense Webster, Diamond Bar,
CA), but was not used as a primary mapping method
(Fig. 2).
Each animal was euthanized while under general anesthe-
sia and without regaining consciousness. Gross pathology
examination of the heart and pericardium was performed
after completion of each experiment. All animals received
humane care in compliance with the European Convention
on Animal Care. The study was approved by the Animal
Care and Use Committee.
Animal results
Mapping equipment was periodically unavailable through-
out the animal lab experience. However, investigators per-
formed simulated mapping using a mapping catheter and
Xuoroscopy. No EP data were collected, but simulated
mapping and ablations were performed under vision. These
animals (4 pigs) were used to test initial features and exam-
ine hemodynamic impact on the heart. Investigators per-
formed Xuoroscopy, direct vision, and ablation, and
explored anatomical areas. By moving the robot back and
forth, they created a simulated map to verify the ability to
deliver various ablation tools (usually 7 Fr Thermocool
Navistar catheters, but in 2 cases a CryoCath Freezor 7 Fr
cryoablation catheter; both Biosense Webster), to visually
identify at-risk structures for ablation, to maintain hemody-
namic viability of the animal throughout the procedure, and
to investigate the heart for signs of damage.
The subsequent studies (5 pigs) involved full system
integration, which included Xuoroscopy, direct vision, and
ablation, and had the additional aim of creating electroana-
tomical maps using the CARTO system. This study per-
formed not only the functions of the simulated maps in the
initial study set, but the results also helped verify the ability
to contact electrodes for epicardial electrogram recordings
controlled by the CardioARM and to generate a ventricular
EP map during sinus rhythm.
Pericardial access was successfully achieved in all ani-
mals. The direct visualization guidance feature of the probe
Fig. 1 CardioARM medical robotic system. a Distal tip of the robotic
system showing the “snakelike” device conforming to a surrogate heart
model. Screens displaying Wberscope vision, robotic controls, and
additional procedural information are in the background. The physi-
cian control device is shown in foreground. b Distal tip of the device,
which operates in the intrapericardial space. Optics are covered by a
dome, and tools channels are shown below123
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tures and precise catheter delivery to the target sites. A
series of isolated ablations was created on the left and right
ventricle. RF delivery (n = 5 hearts) at an irrigation rate of
2–10 cc/min and within an energy range of 20–40 W was
visually observed during application. These ablations were
conWrmed upon postmortem examination (Fig. 2). No sig-
niWcant changes in vital parameters were detected during
probe manipulations, which took 2–3 h in each animal.
During manipulation and positioning of the probe, only
transient arrhythmias were observed that did not require
intervention. In the animal study, we did not attempt to cat-
egorize any arrhythmias that did not require an intervention
to terminate. Per the protocol, animals were not instru-
mented to record continuous real time electrocardiograms.
All animals remained hemodynamically stable throughout
the mapping portion of the procedure. No additional ven-
tricular damage was seen at necropsy other than that from
energy intentionally delivered to the tissue during ablation.
Fluoroscopy veriWcation was part of the validation of the
device and was done in conjunction with the mapping pro-
cedure in early animals. In the last few animals, Xuoros-
copy was delayed until the end of the procedure after full
EP maps had been created.
A summary of the animal investigations is presented in
Table 1.
Human study trial outline enrollment
The single-center, prospective, single-arm study was
designed to evaluate the primary safety and feasibility end-
points of peri-procedural major adverse procedural events
(MAPE) and technical success, respectively. Patients were
followed for 30 days post-index procedure.
Three patients were enrolled in this feasibility trial. All
patients were required to have had at least one documented,
spontaneous episode of sustained, scar-related VT within
the previous 6 months and to be resistant, intolerant, or
refractory to at least one Class I or Class III anti-arrhythmia
drug. Candidates were considered ineligible for any of the
following reasons: previous cardiac surgery or documented
pericarditis; large body habitus or morbid obesity that
would preclude obtaining subxiphoid access to the heart;
other illness that might cause the patient to be noncompli-
ant, confound data interpretation, or be likely to live less
than 6 months after enrollment. Prior to placing the Xexible
robot in the patient, the pericardial space was explored to
rule out adhesions.
The primary safety endpoint for this study was peri-pro-
cedural MAPE, deWned as death, cardiac perforation, coro-
nary artery occlusion (due to energy delivery), or cardiac
tamponade. Subjects were to be evaluated at 48 h post-pro-
cedure or at the time of hospital discharge, whichever
Fig. 2 Representative necropsy showing opening of the pericardium, the CARTO map with radiofrequency (RF) ablation sites marked during
ablation, and corresponding heart following excision123
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MAPE evaluated 30 days post-procedure and (2) overall
adverse events, whether serious or nonserious. The primary
feasibility endpoint was technical success: the ability of the
CardioARM to navigate the EP catheters and create a
CARTO electroanatomic map of the epicardial surface of
the ventricles.
This study was conducted in accordance with the rules of
the institution’s ethicscommittee, country-speciWc regula-
tions, and the Helsinki Declaration of 1975, as revisedin
2008.
Clinical procedure
Each patient underwent the procedure in a hybrid EP-surgi-
cal suite under general anesthesia. After induction of gen-
eral anesthesia, the intended subxiphoid and femoral access
sites were prepped and draped using sterile technique.
Percutaneous femoral arterial/venous sheaths were inserted,
and EP multielectrode catheters were advanced into the
right atrium, coronary sinus, and right ventricle apex. The
surgeon then made a 3- to 6-cm subxiphoid incision and
performed minimal tissue dissection down to the pericar-
dial level. A 15-mm pericardiotomy was performed under
direct visualization over the right ventricle and suspended
with retaining sutures (Fig. 4c).
The Xexible robot was inserted into the pericardial space
and navigated under Wberoptic camera guidance while its
position was being periodically validated with Xuoroscopy.
A Thermocool Navistar catheter was passed through one of
the robot’s internal working channels and was used to cre-
ate ventricular electroanatomical maps using the CARTO
mapping system. Vital physiologic parameters and an intra-
cardiac echocardiogram were continuously monitored
throughout the procedure. Electroanatomical cardiac data
were collected from a catheter deployed through the Xexible
Table 1 Summary of animal investigations
NA not available
a SigniWcant intrapericardial adhesion found. Dissection was performed during mapping procedure









































































108 J Robotic Surg (2013) 7:103–111robot, direct vision was seen from the distal tip of the
device, and periodic Xuoroscopic images were taken at the
discretion of the investigator (Fig. 3).
Delivery of ablative therapy through the investigational
device was left to the discretion of the investigator. After
the procedure, each patient had a short 9 Fr pigtail cathe-
ter (NGC Medical, Como, Italy) placed intrapericardially
through the original incision to help drain any Xuid that
might accumulate.
Human results
The Wrst patient enrolled was a 43-year-old Caucasian
female (weight 82 kg, height 182 cm) in New York Heart
Association (NYHA) Class I heart failure, with an ICD and
a history of multiple unsuccessful attempts of endocardial
RF ablation. The second patient, a 70-year-old Caucasian
male (weight 96 kg, height 178 cm) in NYHA Class II
heart failure, also had an ICD. His history included unsuc-
cessful attempts at RF ablation for both atrial Wbrillation
and VT, and percutaneous coronary intervention and
cardioversion. The third patient was a 67-year-old Cauca-
sian male (weight 86 kg, height 180 cm) in NYHA Class II
heart failure, with a left ventricular ejection function of
25% and an occurrence of VT 17 days prior to enrollment.
His history included one myocardial infarction, one transient
ischemic attack, and ischemic heart disease. The source of
the VT in the latter two patients was suspected to be epi-
cardial.
All three subjects, after subxiphoid pericardial access
was obtained, underwent CARTO electroanatomic map-
ping of the epicardial surface of the right and left ventricles,
using the CardioARM Wtted with a Cordis Biosense
Webster Navistar Thermocool catheter.
Total procedure time, CARTO mapping time, and total
Xuoroscopy time ranged from 96 to 219 min, from 50 to
159 min, and from 11 to 17 min, respectively.
Technical success was achieved in the Wrst and third
patients, but not in the second, where visualization was
obscured by blood originating from outside the pericardial
space. The device was removed to inspect and conven-
tionally control bleeding. Once under control, no attempt
was made to reintroduce the investigational device. Cath-
eter mapping and ablation was performed using a standard
manual technique. No patients experienced a peri-proce-
dural MAPE, as deWned in the safety endpoint, which was
subsequently conWrmed at the 1-week and 30-day follow-
ups. In all trials, a total of three nonserious adverse events
occurred between the time of enrollment and the 30-day
follow-up, but none were attributed to the investigational
device.
A summary of clinical work is presented in Table 2.
Fig. 3 Monitors used during the clinical trial procedure. Information displayed include intracardiac echocardiogram, CARTO, Wberscope vision,
Xuoroscopy (2 monitors), vitals, and robotic status information. Images shown have been superimposed on the monitor bank123
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Animals
Single-site pericardial access, navigation, mapping, and
ablation were successful in all animals, without hemody-
namic compromise. Anatomical structures could be identi-
Wed in all animals, and Xuid management within the
pericardium was successfully managed to maintain direct
view of the space during the entire procedure. Electrode
contact and EP maps were comparable to those of other epi-
cardial approaches previously performed within this institu-
tion, and various imaging modalities were integrated with
the CardioARM without diYculty. All procedures could be
performed using only the robot’s own direct visual guid-
ance, with or without Xuoroscopic assistance. Postmortem
evaluation was consistent with previous work in manual
percutaneous epicardial ablation [9].
Human study
The aim of this clinical investigation, the Wrst known human
use of a snake robot for right and left epicardial ventricular
mapping, was to evaluate whether the consistent positive
Wndings from the porcine model were translatable to the
human anatomy. The intent of this trial was to simply dem-
onstrate initial feasibility of entering the pericardial space
from a single small access point and, in that space, of safely
navigating the robot around a beating heart. Comparisons to
conventional procedures were not examined in this study.
Investigators were able to access the pericardial space
through a subxiphoid entry and navigate the epicardial sur-
face of the ventricles without inducing clinically signiWcant
hemodynamic or arrhythmogenic eVects. The robot pro-
vided direct images of a standard EP mapping catheter, a
suction catheter, and the cardiac surface anatomy of a beat-
ing heart. In two of three subjects, EP maps were success-
fully created with the assistance of the CardioARM
(Fig. 4). The robot exhibited a favorable safety proWle, with
no adverse events attributed to the device. However, based
on the small sample size, it is impossible to draw any con-
clusions other than the initial feasibility.
In the Wrst patient, the robot was challenged when
directed to map at the apex of the heart. However, to
improve the setup, it was believed that the robot could be
better directed towards the apex, or physicians could con-
sider an alternative surgical approach, such as the left chest
to better reach around the apex.
Technical success was not achieved in the second patient.
After a sparse map had been started early in the procedure, a
small amount of blood obscured visualization. Following
device removal, the source was discovered outside the peri-
cardial space, likely generated during the minimally invasive
subxiphoid preparation. Once the bleeding was controlled,
mapping was concluded manually by using Xuoroscopy.
Only a minimal amount (not recorded) of blood was suc-
tioned intraoperatively, and the intrapericardial pigtail place
at the conclusion of the procedure was removed in <24 h
with no unusual amount of Xuid collected.
Limitations and future considerations
The porcine studies using subxiphoid access were a good
model to prepare surgeons for examining CardioARM use
in humans, and they provided insight into the learning
curve. Because the diVerent orientation of the porcine heart
limited analogous understanding of the device in humans,
investigators also tried right chest access in two cases, but
the full range of this approach was not explored. The ani-
mal studies were a reasonable investigation model, but they
did not present all of the challenges expected in a clinical
setting. Finally, histology was never performed. These factors
suggest possible avenues for further study.
Because the clinical trial was so small, certain limita-
tions were inevitable. The three patients fell within a fairly
narrow range of body type, which may have facilitated
navigation of the entire epicardial surface in all cases. VT
ablations were permitted according to the protocol, but
they were never performed, and the procedure was limited
to mapping only. It is untested how the investigational
device would perform during an ablation if a hemody-
namic instability should occur following the delivery of
ablative energy. The failure to reach technical success in the
second patient underscored the importance of maintaining
Table 2 Summary of clinical work
NYHA New York Heart Association





















01 44 182 82 24.8 I 3:39 2:39 None performed 11:13
02 71 178 96 30.3 I 1:41 NAa Conventional 13:00
03 68 180 86 26.5 II 1:36 0:59 Conventional 17:00123
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a beating heart. Further investigation would clarify these
issues.
Several potential technical advances would increase the
range of the Xexible robot’s applicability. It is possible that
in patients with NYHA Class IV heart failure, their
enlarged hearts would create tighter spaces and theoreti-
cally lead to hemodynamic problems. Reducing the size of
the device from its current diameter of 12 mm would
increase the feasibility of treating such patients. The device
maintains its shape during navigation, but also has a safety
feature (not used in this investigation) that enables it to go
limp thereby ensuring that it can be quickly and safely
removed should the need arise, such as in hemodynamic
instability. However, this mechanism, in the device’s cur-
rent form, limits the operator’s ability to pull it back and
pick up electroanatomical points quickly. Therefore, merg-
ing the safety feature with enhanced eYciency is a possible
improvement for the device. Finally, developing a percuta-
neous approach could leverage the Xexible robot to a
diverse set of users and minimize the likelihood of surgical
complications. Instead of relying on surgical access, as in
this study, a speciWc access kit targeted to electrophysiologists,
interventionalists, and cardiac surgeons could increase the
practicality of the product across all specialties.
Conclusion
Following the encouraging results of the porcine studies,
the small clinical trial demonstrated the potential feasibility
and safety of using a Xexible robot system for minimally
invasive epicardial mapping in patients with previous mul-
tiple failed attempts using an endocardial approach. Both
clinical investigation and improved percutaneous access are
required to demonstrate eYcacy.
These results, while limited, show strong promise and
suggest that further clinical investigation of the Cardio-
ARM in patients requiring epicardial mapping of VT is
warranted.
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Fig. 4 Select images during the clinical enrollment. a External view of the setup, b intrapericardial view, c subxiphoid access view, d electroanatomical
CARTO map at the completion of the procedure123
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